Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
Liraglutide
GCG
Thymosin Beta-4
TMSB4X
Liraglutide and Thymosin Beta-4 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Liraglutide is more often discussed in the realm of Metabolic and endocrine, whereas Thymosin Beta-4 is more often associated with the realm of Musculoskeletal health, Cardiovascular health, and Dermatology and aesthetics. Their biological logic is quite different: Liraglutide is a receptor agonist and a hormone analog, whereas Thymosin Beta-4 is a signaling modulator and a protein interaction inhibitor. Liraglutide has a more synthetic analog origin, while Thymosin Beta-4 is closer to natural endogenous background and their development context also differs, with Liraglutide approved while Thymosin Beta-4 is in Clinical phase 2. Liraglutide takes the form of a peptide conjugate, whereas Thymosin Beta-4 is closer to a linear peptide, Liraglutide carries palmitoylation features, while Thymosin Beta-4 instead reflects acetylation changes; while their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and Thymosin Beta-4 showing protein-mimetic sequence features.